Please assess the completion status of the following clinical trial:

Trial Title: Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of both sexes older than 18 years~* Patient diagnosed of CROHN´s disease~* Patient with intestinal stenosis length equal or less than 5cm previously confirmed with bowel magnetic resonance imaging (3 stenosis as maximum)~* Stenosis no permeable for endoscopy(12mm in case of accessible stenosis with conventional colonoscopy and 10mm in case of accessible stenosis with balloon enteroscopy)~* Dilated stenosis according to endoscopist criteria (pass or no the endoscopy)~* Patient capable of participate in the examinations required by the study~* Patient after being informed, give his/her informed consent in writing~Exclusion Criteria:~* Patients with large intestinal stenosis (more than 6cm) and multiples~* Patients with previous or actual treatment with anti-tumor necrosis factor (anti-TNF) drugs~* Patients with positive serology to hepatitis B virus(HBV),hepatitis C virus (HCV), or HIV~* Patients with positive screening to Tuberculosis(positive PPD)~* Established contraindication to anti-TNF drugs~* Existence of fistulous tracts associated with intestinal stenosis~* Neoplastic process associated with stenosis or in another location~* Pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: EXPERIMENTAL): single administration of Adalimumab 80mg diluted in 5ml saline
- saline (Type: PLACEBO_COMPARATOR): 5 ml of saline

Based on this trial design, predict the completion outcome and termination type (if applicable).